Literature DB >> 30328372

Prevention of type 2 diabetes: what is the right target population?

Donald A Williamson1.   

Abstract

INTRODUCTION: Prevention of type 2 diabetes (T2D) is important to reduce suffering and health care costs. A precursor to T2D is impaired glucose regulation (IGR), a condition of elevated plasma glucose that is associated with insulin resistance and increased risk of cardiovascular disease. Prevention of T2D is determined by preservation of pancreatic β cell function which can be achieved by the use of anti-hyperglycemic medications or intensive lifestyle interventions (ILIs) to modify dietary and physical activity habits that induce modest weight loss (≥5%). Both interventions have beneficial effects on normal glucose regulation (NGR), but ILI is preferred due to its safety, efficacy, and cost. AREAS COVERED: Traditional approaches to the prevention of T2D have used a variety of screening methods to identify those who are at high risk for developing T2D (prediabetes). People designated with prediabetes are then treated with ILI. An alternative approach for preventing T2D is to offer ILI to all overweight/obese adults who volunteer for weight loss treatment. EXPERT COMMENTARY: This new alternative has several potential advantages: more rapid recruitment of participants with lower burden of care and early, aggressive treatment of potential β cell dysfunction. Cost-effectiveness studies of this alternative approach are needed.

Entities:  

Keywords:  Intensive lifestyle interventions; obesity; overweight; prediabetes; prevention; screening; type 2 diabetes

Mesh:

Year:  2018        PMID: 30328372     DOI: 10.1080/17446651.2018.1535896

Source DB:  PubMed          Journal:  Expert Rev Endocrinol Metab        ISSN: 1744-6651


  1 in total

Review 1.  The Effects of Asprosin on Exercise-Intervention in Metabolic Diseases.

Authors:  Lifei Liu; Yuhao Liu; Mei Huang; Miao Zhang; Chenyu Zhu; Xi Chen; Samuel Bennett; Jiake Xu; Jun Zou
Journal:  Front Physiol       Date:  2022-07-11       Impact factor: 4.755

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.